Headwaters Capital Management released its second-quarter 2025 investor letter, with the portfolio gaining +7.5% compared to a +8.5% gain for the Russell Mid Cap Index. The letter highlighted TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company whose stock closed at $116.88 per share, with a market capitalization of $3.954 billion on July 14, 2025. The top contributor for Q2 ’25 was TransMedics Group, Inc. (TMDX) with a 98% increase. The company reported total revenue of $143.5 million for 1Q 2025, reflecting a year-over-year growth of about 48%. Hedge funds are holding TMDX, but there are other AI stocks with greater potential.

Read more at Yahoo Finance: Headwaters Capital Management Sold Transmedics (TMDX) After a Strong Q1 Report